# Who does Incyte Corporation pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/incyte · Facet: suppliers · Updated: 2026-09-24T05:06:14.454257+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Incyte Corporation discloses no named confirmed suppliers/cost counterparties; 2 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 2 cost edges, backed by 1 dated sources, 1 of them primary filings (as of 2026-09-24).

### MacroGenics (high)
- metric: Amount $215M · Agreement inception through FY2025 · Cumulative development and regulatory milestones paid to MacroGenics
- note: Incyte licensed worldwide development and commercialization rights to the anti-PD-1 antibody INCMGA0012 from MacroGenics, which also retained rights to manufacture part of the clinical and commercial supply. Cumulative development and regulatory milestone payments reached $215 million through FY2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-10) https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm: "Through December 31, 2025, we have paid MacroGenics developmental and regulatory milestones totaling $215.0 million."

### Syndax Pharmaceuticals (high)
- metric: Amount $44M · FY2025 · Syndax's profit share from U.S. co-commercialization of NIKTIMVO
- note: Incyte and Syndax split U.S. commercialization profit and loss for NIKTIMVO equally. Syndax's $44 million share of FY2025 profit was recorded in Incyte's cost of product revenue.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-10) https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm: "Syndax's 50% share of profit was $44.0 million for the year ended December 31, 2025."

### Prelude Therapeutics (high)
- metric: Amount $25M · November 2025 · Principal amount of the equity investment in Prelude Therapeutics non-voting common stock
- note: Incyte secured an exclusive option over Prelude's JAK2V617F program and bought 6.25 million non-voting common shares at $4 per share. The equity investment totaled $25 million.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-10) https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm: "We paid Prelude a total of $60.0 million ... plus a $25.0 million equity investment."

Reverse side: https://valuechain.wiki/incyte/customers.md · Ripple: https://valuechain.wiki/incyte/ripple.md

---
Full node: https://valuechain.wiki/incyte.md · JSON: https://valuechain.wiki/incyte.json